Shares of rare disease giant Vertex Pharmaceuticals (NASDAQ: VRTX) are poised for a major sell-off today. The company's shares fell by as much as 14.5% in pre-market trading Friday morning in response to the biotech's decision to discontinue the clinical program for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin (AATD). AATD is an inherited condition that results in a misfolded AAT protein in the blood.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting